Denali Therapeutics

Overview

Denali Therapeutics Inc. is a American biotechnology company headquartered in South San Francisco, California, focused on developing therapies for neurodegenerative diseases. Founded in 2013 as a spinout from Genentech, Denali is a leader in LRRK2 inhibitors for Parkinson's disease and has a broad pipeline in Alzheimer's disease, ALS, and other neurological conditions. [@denali]

Company Overview

Overview

Denali Therapeutics Inc. is a American biotechnology company headquartered in South San Francisco, California, focused on developing therapies for neurodegenerative diseases. Founded in 2013 as a spinout from Genentech, Denali is a leader in LRRK2 inhibitors for Parkinson's disease and has a broad pipeline in Alzheimer's disease, ALS, and other neurological conditions. [@denali]

Company Overview

| Attribute | Details | [@biogen]
|-----------|---------| [@lrrk2021]
| Ticker | NASDAQ: DNLI | [@luma]
| Headquarters | South San Francisco, California, USA | [@trem]
| Founded | 2013 |
| CEO | Carole Ho |
| Employees | ~450 |
| Market Cap | ~$2.5 billion (2024) |

Parkinson's Disease Pipeline

Lead Program: LRRK2 Inhibitors

| Drug | Mechanism | Phase | Indication |
|------|-----------|-------|------------|
| DNL151 (BIIB122) | LRRK2 inhibitor | Phase 2b | Parkinson's disease |
| DNL151 | LRRK2 inhibitor | Phase 1 (Japan) | Parkinson's disease |
| DNL261 | LRRK2 inhibitor | Phase 1 | Parkinson's disease |

DNL151 (BIIB122)

• Mechanism: LRRK2 kinase inhibitor
• Target: Leucine-rich repeat kinase 2 (LRRK2)
• Phase: Phase 2b (LUMA study)
• Partner: Biogen (co-development and co-commercialization)
• Status: Recruiting
• Clinical Trials: [LUMA](https://clinicaltrials.gov/show/NCT04056689), [NCT03976375](https://clinicaltrials.gov/show/NCT03976375)
• Rationale: LRRK2 mutations are a major genetic risk factor for Parkinson's disease; inhibition may slow disease progression

Other Parkinson's Programs

DNL343

• Mechanism: eIF2B activator
• Target: Integrated stress response
• Phase: Phase 1
• Rationale: Modulate cellular stress response in neurodegeneration

Alzheimer's Disease Pipeline

| Drug | Mechanism | Phase | Indication |
|------|-----------|-------|------------|
| DNL919 (ARCAM-1) | TREM2](/proteins/trem2) agonist | Preclinical | AD |
| DNL593 | - | Discovery | AD |
| DNL788 | - | Discovery | AD |

DNL919 (ARCAM-1)

• Mechanism: TREM2 agonist antibody
• Target: TREM2 (Triggering Receptor Expressed on Myeloid Cells 2)
• Phase: Preclinical
• Rationale: TREM2 variants are genetic risk factors for Alzheimer's; agonism may enhance microglial function

Other Neurological Programs

ALS (Amyotrophic Lateral Sclerosis)

| Drug | Mechanism | Phase |
|------|-----------|-------|
| DNL788 | - | Phase 1 (planned) |
| DNL558 | - | Discovery |

Hunter Syndrome (MPS II)

| Drug | Mechanism | Phase |
|------|-----------|-------|
| DNL310 (ENHANZE) | Enzyme replacement (IDS) | Phase 2/3 |

DNL310 (ENHANZE)

• Mechanism: Iduronate-2-sulfatase (IDS) enzyme with Brain Transport Vehicle (TVB)
• Target: Central nervous system delivery of enzyme
• Phase: Phase 2/3
• Partner: Takeda (license agreement)
• Status: Recruiting

Scientific Platforms

Brain Transport Vehicle (TVB)

• Application: Used in DNL310 (Hunter syndrome) and other CNS programs
• Mechanism: Transcytosis via receptor-mediated transport

Small Molecule LRRK2 Inhibitors

• Design: Highly brain-penetrant, selective LRRK2 inhibitors
• Advantage: Good CNS penetration, safety profile suitable for chronic dosing

TREM2 Agonists

• Approach: monoclonal antibodies that activate TREM2 signaling
• Rationale: Enhance microglial function in Alzheimer's disease

Strategic Partnerships

Biogen Partnership (LRRK2)

• Scope: Co-development and co-commercialization of LRRK2 inhibitor program
• Structure: 50/50 profit sharing in US; Denali leads development, Biogen leads commercialization
• Deal Date: 2020
• Value: $1.1B upfront and milestones

Takeda Partnership (MPS II)

• Scope: License to DNL310 (ENHANZE) for Hunter syndrome
• Structure: Takeda leads commercialization; Denali receives royalties
• Deal Date: 2022

Other Partnerships

• F-star Therapeutics - Reserved protein platform for TREM2 program
• Various academic collaborations for biomarker development

Financial Highlights

| Year | Revenue | Cash | Key Programs |
|------|---------|------|--------------|
| 2023 | $67M | $650M | LRRK2, DNL310 |
| 2022 | $50M | $700M | LRRK2, DNL310 |
| 2021 | $25M | $750M | LRRK2 |

Clinical Trials

• LRRK2 trials](https://clinicaltrials.gov/search?cond=Parkinson%27s%20disease&spons=Denali+Therapeutics) - Multiple ongoing
• [DNL310 trials](https://clinicaltrials.gov/search?cond=Hunter+syndrome&spons=Denali+Therapeutics) - Phase 2/3

Key Leadership

• Carole Ho - CEO (former Genentech)
• Eric K. Green - Chief Scientific Officer
• William (Bill) J. R. C. Lee - Co-founder and Chairman

Funding and Financial History

Initial Public Offering

• IPO: May 2017 (NASDAQ: DNLI)
• Raised $250 million in initial public offering at $18/share
• Market cap at IPO: approximately $1.8 billion

Major Funding Rounds (Pre-IPO)

• Series A: 2015, $50 million (lead investors not disclosed)
• Series B: 2016, $100 million (including Google Ventures, Arrowview Partners)
• Series C: 2017, $150 million (before IPO)

Key Partnerships

• Biogen: Co-development and co-commercialization agreement for LRRK2 inhibitors (DNL151/BIIB122)
• Deal value: $460 million upfront + $1.1 billion in milestones
• Takeda: Collaboration on blood-brain barrier transport technology (AV-101)
• Genentech: Original founding partnership (founder from Genentech)

Market Position

• Leading biotechnology company in LRRK2 inhibitors for Parkinson's disease
• Strong foundation expertise in neurodegenerative diseases from Genentech roots
• Diversified pipeline across AD, PD, ALS, and other neurological conditions
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Amyloid Cascade Hypothesis](/mechanisms/amyloid-cascade)
• [Tau Pathology](/mechanisms/tau-pathology)
• [TREM2](/proteins/trem2)
• [LRRK2](/genes/lrrk2)
• [Blood-Brain Barrier](/mechanisms/blood-brain-barrier-dysfunction)
• [Clinical Trials Overview](/clinical-trials)
• [Biogen](/companies/biogen)
• [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)

External Links

• [ClinicalTrials.gov Search](https://clinicaltrials.gov/search?spons=Denali+Therapeutics)

References